- As per Serum Institute of India, the COVID-19 vaccines will be available less than Rs250 per dose.
- The vaccine will be available as nearly as the first half of 2021 after getting approval from the World Health Organization (WHO).
- The institute has collaborated with Gavi, the vaccine alliance, and the Bill and Melinda Gates Foundation as a part of the COVAX agreement.
The COVID-19 vaccine will be available as the first half of 2021 after getting approvals and qualifications from the World Health Organization (WHO)
Furthermore, If this gets successful, Novavax’s candidate will be available to all 92 countries who have been affected by COVID-19. while AstraZeneca’s candidate vaccine will be available to 57 Gavi-eligible countries.
For the better results of this development, The Serum institute has collaborated with Gavi, the Vaccine Alliance, and the Bill & Melinda Gates Foundation as part of the COVAX agreement. Under this agreement, The institute will receive upfront capital of Rs1.12K crores (approx) or $150M from Bill & Melinda Gates Foundation via Gavi to improve the product development and its distribution on a large scale after gaining regulatory approval from the World Health Organization (WHO).
Moreover, “India has demonstrated consistent capability in delivering low-cost and high-quality medical research, while also maintaining technical and scientific rigour. ICMR is deeply supportive of our cutting edge vaccine research and manufacturing prowess, of which Serum Institue is one prominent example. This partnership signifies yet another step in India’s efforts to bolster the fight against this global pandemic.” said, Dr. Balram Bhargava, Director General of Indian Council of Medical Research (ICMR).
According to the agreements signed by SII, for the supply of COVID-19 vaccines, the first being AstraZeneca-Oxford’s, for the which the country agreed to produce up to 1 Billion doses for low-middle classes people.
The second agreement is with the U.S-based Novavax that has granted the company for its exclusive and non-exclusive licenses for the development, filling and finishing, registration, and commercialization of its NVX-CoV2373 vaccine product for the SARS-CoV-2 virus. Trials are yet to start in India.